Best known globally for its aspirin and locally for its life-saving hemophilia treatments, drug giant Bayer is firming up plans to lead one of biotech's hottest areas with a pioneering new cell therapy manufacturing facility on its fast-changing Berkeley campus.
The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
By Joy Zhang, Progress Educational Trust | 08.12.2024
Aggregated News
What do China's new ethical guidlines tell us about the country's changing attitude to human genome editing? Professor Joy Zhang reads between the lines...
Recently, China's National Science and Technology Ethics Committee introduced a new set of ethics guidelines on...
Despite major advances in securing sexual and reproductive rights globally, one aspect is continually neglected: infertility. Evolving gender norms and financial precariousness have led to delayed childbearing, which increases infertility in both males and...
I started reading JD Vance's 2016 memoir "Hillbilly Elegy" on election day, 2020. I didn’t plan it this way. I’d been asked to review the film and I...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.